| P50 | author | Djillali Annane | Q30004548 |
| P2860 | cites work | Physiological-dose steroid therapy in sepsis [ISRCTN36253388] | Q21195121 |
| | Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective | Q24293646 |
| | Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care | Q27860820 |
| | Hydrocortisone therapy for patients with septic shock | Q28264225 |
| | Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine | Q28280888 |
| | Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 |
| | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 | Q29615602 |
| | Corticosteroids: way upstream | Q33738920 |
| | Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study | Q33861751 |
| | A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin | Q33891791 |
| | Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock | Q34145159 |
| | Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death | Q34455153 |
| | Reversal of late septic shock with supraphysiologic doses of hydrocortisone | Q34465500 |
| | Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock | Q34466069 |
| | Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis | Q34999600 |
| | Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. | Q35831218 |
| | Glucocorticoids in the treatment of severe sepsis and septic shock | Q36262817 |
| | Randomized trials stopped early for benefit: a systematic review | Q36303650 |
| | Recombinant human activated protein C: current insights into its mechanism of action | Q37082968 |
| | Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. | Q37513002 |
| | Activated protein C for sepsis | Q37665097 |
| | Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial | Q38376133 |
| | Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. | Q40235280 |
| | Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. | Q40453111 |
| | Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. | Q40460082 |
| | Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor | Q40657744 |
| | Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. | Q44315236 |
| | Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes | Q50281724 |
| | Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* | Q64126934 |
| | Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation | Q68030002 |
| | Survival of primates in lethal septic shock following delayed treatment with steroid | Q70159244 |
| | GLucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity | Q70473760 |
| | Effect of glucocorticosteroids on some coagulation tests | Q71622448 |
| | Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation | Q73987371 |
| | Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis | Q78836710 |
| | Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated) | Q80447715 |
| | Septic shock | Q81245367 |
| | Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial | Q81574798 |
| P433 | issue | 5 | |
| P921 | main subject | sepsis | Q183134 |
| P304 | page(s) | 361-367 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Current infectious disease reports | Q26842136 |
| P1476 | title | Adjunct therapy for sepsis: how early? | |
| P478 | volume | 12 | |